Európska únia - slovenčina - EMA (European Medicines Agency)

beigene ireland ltd - zanubrutinib - waldenstrom macroglobulinemia - antineoplastické činidlá - brukinsa as monotherapy is indicated for the treatment of adult patients with waldenström’s macroglobulinaemia (wm) who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo-immunotherapy. brukinsa as monotherapy is indicated for the treatment of adult patients with marginal zone lymphoma (mzl) who have received at least one prior anti-cd20-based therapy. brukinsa as monotherapy is indicated for the treatment of adult patients with chronic lymphocytic leukemia (cll).

Európska únia - slovenčina - EMA (European Medicines Agency)

novartis europharm limited - tislelizumab - esophageal squamous cell carcinoma - antineoplastické činidlá - oesophageal squamous cell carcinoma (oscc) tevimbra as monotherapy is indicated for the treatment of adult patients with unresectable, locally advanced or metastatic oesophageal squamous cell carcinoma after prior platinum-based chemotherapy.

Európska únia - slovenčina - EMA (European Medicines Agency)

celgene europe bv - azacitidín - myelodysplastic syndromes; leukemia, myelomonocytic, chronic; leukemia, myeloid, acute - antineoplastické činidlá - azacitidine celgene is indicated for the treatment of adult patients who are not eligible for haematopoietic stem cell transplantation (hsct) with:intermediate 2 and high-risk myelodysplastic syndromes (mds) according to the international prognostic scoring system (ipss),chronic myelomonocytic leukaemia (cmml) with 10 29 % marrow blasts without myeloproliferative disorder,acute myeloid leukaemia (aml) with 20 30 % blasts and multi-lineage dysplasia, according to world health organisation (who) classification,aml with >30% marrow blasts according to the who classification.

Európska únia - slovenčina - EMA (European Medicines Agency)

celgene europe ltd. - lepirudínom - thromboembolism; thrombocytopenia - antitrombotické činidlá - antikoagulácia u dospelých pacientov s heparínom indukovanou trombocytopéniou typu ii and tromboembolickým ochorením liečených parenterálnou antitrombotickou terapiou. diagnóza by mala byť potvrdená heparín-indukovanej doštičiek aktiváciu testu alebo rovnocenné skúšky.

Európska únia - slovenčina - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - talidomid - viacnásobný myelóm - imunosupresíva - thalidomide bms in combination with melphalan and prednisone as first line treatment of patients with untreated multiple myeloma, aged >/= 65 years or ineligible for high dose chemotherapy. thalidomide bms is prescribed and dispensed according to the thalidomide celgene pregnancy prevention programme (see section 4.

Slovensko - slovenčina - ŠÚKL (Štátny ústav pre kontrolu liečiv)

digene corporation 1201 clopper road gaithersburg, maryland spojené štáty americké -

Slovensko - slovenčina - ŠÚKL (Štátny ústav pre kontrolu liečiv)

digene corporation 1201 clopper road gaithersburg, maryland spojené štáty americké -

Slovensko - slovenčina - ŠÚKL (Štátny ústav pre kontrolu liečiv)

digene corporation 1201 clopper road gaithersburg, maryland spojené štáty americké -

Slovensko - slovenčina - ŠÚKL (Štátny ústav pre kontrolu liečiv)

digene corporation 1201 clopper road gaithersburg, maryland spojené štáty americké -

Európska únia - slovenčina - EMA (European Medicines Agency)

celgene europe ltd. - romidepsin - lymfóm, non-hodgkin - antineoplastické činidlá - liečby periférnych t-bunkového lymfómu (ptcl),.